Perspective Therapeutics (NYSE:CATX) Earns "Outperform" Rating from Wedbush

Wedbush reissued their outperform rating on shares of Perspective Therapeutics (NYSE:CATX - Free Report) in a research report sent to investors on Monday,RTT News reports. The brokerage currently has a $11.00 target price on the stock.

Other research analysts have also recently issued reports about the company. Oppenheimer reduced their price target on Perspective Therapeutics from $22.00 to $16.00 and set an "outperform" rating for the company in a research report on Friday, November 22nd. Cantor Fitzgerald raised shares of Perspective Therapeutics to a "strong-buy" rating in a report on Tuesday, March 4th. Brookline Capital Management upgraded Perspective Therapeutics to a "strong-buy" rating in a research note on Monday, March 10th. Lifesci Capital raised shares of Perspective Therapeutics to a "strong-buy" rating in a research note on Thursday, March 6th. Finally, Bank of America lowered Perspective Therapeutics from a "buy" rating to a "neutral" rating and dropped their price target for the company from $24.00 to $5.00 in a research report on Monday, November 25th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, Perspective Therapeutics currently has a consensus rating of "Buy" and an average target price of $14.56.

Remove Ads

Perspective Therapeutics Stock Performance

NYSE CATX traded down $0.03 on Monday, hitting $2.47. 194,133 shares of the company's stock traded hands, compared to its average volume of 983,708. The firm's 50-day moving average price is $3.05 and its two-hundred day moving average price is $6.96. Perspective Therapeutics has a 1-year low of $2.32 and a 1-year high of $19.05.

Institutional Trading of Perspective Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. increased its holdings in shares of Perspective Therapeutics by 221.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company's stock valued at $5,788,000 after acquiring an additional 298,778 shares during the period. State Street Corp increased its stake in Perspective Therapeutics by 119.6% in the third quarter. State Street Corp now owns 2,190,239 shares of the company's stock valued at $29,240,000 after purchasing an additional 1,192,812 shares during the period. Janus Henderson Group PLC boosted its stake in shares of Perspective Therapeutics by 8.0% during the third quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company's stock worth $64,014,000 after buying an additional 355,685 shares during the period. FMR LLC grew its holdings in shares of Perspective Therapeutics by 3,994.9% during the third quarter. FMR LLC now owns 5,504,822 shares of the company's stock worth $73,489,000 after buying an additional 5,370,392 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its stake in Perspective Therapeutics by 1,302.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 47,565 shares of the company's stock valued at $635,000 after acquiring an additional 44,174 shares during the last quarter. 54.66% of the stock is owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.